Bering Capital
Venture capitalActively deployingSan Francisco · Seed–Growth · 9 people tracked
Find your way into Bering Capital
Sign up to see every warm intro you have to Bering Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bering Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Bering Capital emphasizes the primacy of great markets and great people aligned around a shared mission. The firm positions itself as a seasoned partner that supports companies through varied stages of growth, helping build fundamentally strong businesses by establishing early culture and trust. It stresses strategic insight applied early in a company's development, reliable expertise amid market volatility, and a forward-looking, visionary approach to building innovative businesses. Its publicized news centers on healthcare and oncology companies such as Coherus and CalciMedica, suggesting a strong orientation toward transforming healthcare and life sciences.
Source: firm website, verified Oct 25, 2026.
Team · 9 people
from the firm's website & curated & public directoriesManaging Partner at Bering Capital, holding MD and PhD credentials.
Managing Partner at Bering Capital.
Advisor to Bering Capital, holding a DPhil.
Advisor to Bering Capital, holding a PhD.
Advisor to Bering Capital, holding an MD.
Advisor to Bering Capital, holding an MD.
Gregory B. Brown, M.D. is CEO and a director of Memgen, Inc., a development-stage company working on next-generation viral immunotherapeutics including oncolytic viruses. He co-founded HCR Partners, a healthcare-focused asset management firm, and was previously a partner at Paul Capital Partners where he co-managed royalty investments; earlier he was co-head of investment banking and head of healthcare at Adams, Harkness & Hill and a biotechnology research analyst at Vector Securities International. Trained as a transplantation immunologist and thoracic and vascular surgeon, he holds a B.A. from Yale College, an M.D. from SUNY Upstate Medical Center, and an M.B.A. from Harvard Business School.
What they invest in
from 6 of 15 portfolio companiesBiotech ×5Healthtech ×5Medical Devices ×2AI & Machine Learning ×1Digital Health ×1
HQs:United States×5
Investments · 15 tracked
founders shown can be your intro pathAtea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).
BiotechHealthtechBoston, US
Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)Janet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in
Co-investorsATEM Capital FundBain Capital Life SciencesRA Capital
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
BiotechHealthtechLa Jolla, US
Kenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Michael J. Dunn(Executive Officer)inStephen Bardin(Chief Financial Officer)in
Co-investorsAisling CapitalMESA VERDE VENTURE PARTNERSRevelation PartnersSanderling VenturesClarus VenturesOrbiMed
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.
BiotechHealthtechMedical DevicesRedwood City, US
Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)inJean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)
Co-investorsF-Prime CapitalHEALTHCARE ROYALTY PARTNERSSofinnova VenturesVenrock
Life Detection Technologies (LDT) develops a machine-learning platform that monitors core vital signs such as overnight heart rate and respiratory rate to predict COPD exacerbations days before they occur.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US
Peter Rule(CEO)inEric Howie(Executive Officer, Director)Dave Vreeland(Director)Marc Thomas(Director)
BoardEarl Cohen(Board Member)
Co-investorsGoAhead VenturesInnova Memphis, Inc.
NEUVOGEN is a biotechnology company developing therapeutic cancer vaccines, using a whole tumor cell vaccine platform aimed at addressing the complexity of solid tumors.
BiotechHealthtech
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaARCH Venture Partners+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CellworksCoherus OncologyDragon VascularFocalThericsFusion MedicalInvuityLeap TherapeuticsOnco ResponsePrecision Pharmaceuticals Holdings
Exits · 3
3 IPOsAtea PharmaceuticalsNASDAQ: AVIRCalcimedicaNASDAQ: CALCCoherus BiosciencesNASDAQ: CHRS
Portfolio news
latest coverage across their companiesFrequently asked questions
- How many investments has Bering Capital made?
- Bering Capital has 15 tracked investments, 3 of which have exited.
- What stage does Bering Capital invest at?
- Bering Capital invests at the Seed, Series A, Growth stages.
- What sectors does Bering Capital focus on?
- Bering Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is Bering Capital located?
- Bering Capital is headquartered in San Francisco, US.
- Who does Bering Capital co-invest with?
- Bering Capital most often shares deals with F-Prime Capital, GoAhead Ventures, Sanderling Ventures, among 13 tracked co-investors.
Images
Similar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Sandbox Industries is an investment firm focused on healthcare and insurance, partnering with industry stakeholders as strategic limited partners alongside financial investors and its portfolio companies.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools, devices, biochemistry-based technologies, and digital health applications. It also builds companies of its own.
OneVentures is an Australian later-stage venture capital firm that invests in and scales technology and healthcare companies through growth equity, growth credit and life sciences investments.
Hitachi Ventures is the corporate venture arm of Hitachi, investing in founders building world-changing innovation across digital, industrial, environment, and healthcare themes.




































